Efficacy and tolerability of urate-lowering drugs in gout: A randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol

Annals of the Rheumatic Diseases

Volumn 68, Issue 1, 2009, Pages 51-56

  Reinders, M K ^a,b,e   Van Roon, E N ^a,b   Jansen, T L Th A ^a   Delsing, J ^c   Griep, E N ^a   Hoekstra, M ^c   Van De Laar, M A F J ^d   Brouwers, J R B J ^a,b  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d UNIVERSITY OF TWENTE   (Netherlands)

^e Sittard Geleen Heerlen   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; COLCHICINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROBENECID; PROBENECID WEIMER; UNCLASSIFIED DRUG; URATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; GOUT; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MYALGIA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT FAILURE; URIC ACID BLOOD LEVEL; VISUAL DISORDER;

AGED; ALLOPURINOL; BENZBROMARONE; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; PROBENECID; PROSPECTIVE STUDIES; TREATMENT FAILURE; URIC ACID;

EID: 58449135143     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2007.083071     Document Type: Article

References (49)

1. Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout-a systematic review. Rheumatology 2006; 45:1422-31.
2. Van der Klauw MM, Houtman PM, Stricker BH, Spoelstra P. Hepatic injury caused by benzbromarone. J Hepatol 1994; 20:376-9.
3. Wagayama H, Shiraki K, Sugimoto K, Fujikawa K, Shimizu A, Takase K, et al. Fatal fulminant hepatic failure associated with benzbromarone. J Hepatol 2000; 32:874.
4. Arai M, Yokosuka O, Fujiwara K, Kojima H, Kanda T, Hirasawa H, et al. Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol 2002; 17:625-6.
5. Masbernard A, Giudicelli CP. Ten years' experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med J 1981; 59:701-6.
6. Conaghan PG, Day RO. Risks and benefits of drugs used in the management and prevention of gout. Drug Saf 1994; 11:252-8.
7. Choi KH, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005; 143:499-516.
8. Terkeltaub RA. Gout. N Engl Med J 2003; 349:1647-55.
9. Rott KT, Agudelo CA. Gout. JAMA 2003; 289:2857-60.
10. Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005; 17:319-24.
11. Jansen TL, Reinders MK, van Roon EN, Brouwers JR. Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"? Clin Exp Rheumatol 2004, 22:651.
12. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312-24.
13. Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28:577-80.
14. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51:321-5.
15. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006; 12:61-5.
16. Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during antihyperuricemic treatment. Adv Exp Med Biol 1998; 431:13-18.
17. Perez-Ruiz F, Calabozo M, Pijoan Jl, Herrero-Beites AM, Ruibal A. Effect of uratelowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47:356-60.
18. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford) 2007; 46:1372-4.
19. Pascual E, Batlle-Gualda E, Martinez A, Rosas J, Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 1999; 131:756-9.
20. Wallace SL, Robinson H, Masi AT, Decker JL, McCarthy DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20:895-900.
21. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47-56.
22. Cockcroft DW, Gault MD. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
23. Kaehny WD, Tangel DJ, Johnson AM, Kimberling WJ, Schrier RW, Gabow PA. Uric acid handling in autosomal dominant polycystic kidney disease with normal filtration rates. Am J Med 1990; 89:49-52.
24. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353:2450-61.
25. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz- Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57:545-9.
26. Hanvivadhanakul P, Akkasilpa S, Deesomchok U. Efficacy of benzbromarone compared to allopurinol in lowering serum urate level in hyperuricemic patients. J Med Assoc Thai 2002; 85:S40-7.
27. Reinders MK, Nijdam LC, van Roon EN, Movig KL, Jansen TL, van de Laar MA, et al. A simple method for guantification of allopurinol and oxipurinol in human serum by high-performance liquid chromatography with UV-detection. J Pharm Biomed Anal 2007, 45:312-17.
28. Reinders MK, Van Roon EN, Houtman PM, Brouwers JR, Jansen TL. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromaronetreated gout patients. Clin Rheum 2007; 26:1459-65.
29. Perez-Ruiz F, Lioté F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007; 57:1324-8.
30. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med 1966; 64:229-58.
31. Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacol 2007; 46:623-44.
32. Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993; 27:337-43.
33. Kumar A, Edward N, White Ml. Johnston PW, Catto GR. Allopurinol, erythema multiforme, and renal insufficiency. BMJ 1996; 312:173-4.
34. Braden GL, Warzynski MJ, Golightly M, Ballow M. Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin Immunol Immunopathol 1994; 70:145-51.
35. * 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102:4134-9.
36. Schlesinger N. Management of acute and chronic gouty arthritis: present state-ofthe-art. Drugs 2004, 64:2399-416.
37. Mclnnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis 1981; 40:245-9.
38. Hande K, Reed E, Chabner B. Allopurinol kinetics. Clin Pharmacol Ther 1978; 23:598-605.
39. Walshaw PE, McCauley FA, Wilson TW. Diuretic and non-diuretic actions of furosemide: effects of probenecid. Clin Invest Med 1992; 15:82-7.
40. Scott JT. Comparison of allopurinol and probenecid. Ann Rheum Dis 1966; 25:623-6.
41. Boger WP, Strickland SC. Probenecid (Benemid); its uses and side-effects in 2,502 patients. Arch Intern Med 1955; 95:83-92.
42. Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002; 47:610-13.
43. Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 2005; 20:431-3.
44. Moolenburgh JD, Reinders MK, Jansen TL. Rasburicase treatment in severe tophaceous gout; a novel therapeutic option. Clin Rheumatol 2006; 25:749-52.
45. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006; 8:R12.
46. Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007; 56:1021-8.
47. Kleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, et al. The impact of gout on work absence and productivity. Value Health 2007; 10:231-7.
48. Fam AG. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Curr Rheumatol Rep 2001; 3:29-35.
49. Kumar S, Ng J, Gow P. Benzbromarone therapy in management of refractory gout. N Z Med J 2005; 118:U1528.